Across TCGA pan-cancer cohorts, MIR558 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of MIR558’s most consistent transcriptional readouts.
The strongest signal is observed in stomach adenocarcinoma (STAD), where MIR558 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR558 is over-expressed in tumor.
STAD are the cancer types where MIR558 tumor–normal differential expression is most reproducible.